15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

      Clinical Pharmacology and Therapeutics
      Antimetabolites, Antineoplastic, administration & dosage, adverse effects, Deoxycytidine, analogs & derivatives, Dihydropyrimidine Dehydrogenase Deficiency, diagnosis, genetics, Dihydrouracil Dehydrogenase (NADP), Female, Fluorouracil, Genotype, Humans, Incidental Findings, Male, Risk Assessment, Sex Factors, Tegafur

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

          Related collections

          Author and article information

          Comments

          Comment on this article